How safe is Stem Cell Therapy for Multiple Sclerosis (MS)?
Stem cell therapy with mesenchymal stromal cells (MSCs) has shown a favorable safety profile in people with multiple sclerosis (MS).

In the MESEMS trial, an international randomized, double-blind, placebo-controlled study published in The Lancet Neurology in 2021, intravenous (IV) MSC infusions were safe in people with active MS. Across many conditions, large analyses of randomized trials show that the most consistent side effect of IV MSCs is a temporary fever, without increased infections, blood clots, cancer or death. Two MS-specific points matter for safety: fever can temporarily worsen existing MS symptoms (a pseudo-relapse), and many people with MS take immune-modifying medications that need careful review. It is also important to distinguish MSC therapy from autologous hematopoietic stem cell transplantation (aHSCT), an intensive procedure with chemotherapy that has stronger evidence for controlling inflammatory MS but carries much higher risks. At Stem Cell Mexico, MS protocols use allogeneic MSCs from umbilical cord tissue, usually by IV infusion, with screening and monitoring.
This guide explains the safety of each approach, MS-specific considerations and how risks are minimized.
Two very different stem cell treatments, two different safety profiles
Mesenchymal stromal cell (MSC) therapy
- Given without chemotherapy, usually by IV infusion, with a short stay.
- Aims to modulate immune activity and support neuroprotection.
- Most common side effects: temporary fever, headache and fatigue.
- Serious complications uncommon in controlled trials.
Autologous hematopoietic stem cell transplantation (aHSCT)
- Involves collecting the patient's own blood stem cells, giving chemotherapy to largely eliminate the immune system and reinfusing the stem cells.
- The MS International Federation (MSIF) describes it as an intensive treatment with significant risks, including life-threatening complications such as serious infections, and it requires weeks of specialized hospital care.
- A randomized trial in JAMA (Burt and colleagues, 2019) showed reduced disability progression with aHSCT compared with continued disease-modifying therapy in highly active relapsing MS, which is why it is used in selected patients at specialized transplant centers.
These treatments should never be compared directly in terms of price, risk or expected results.
What the evidence shows for MSC safety
MESEMS trial
This phase 2 crossover trial randomized people with active relapsing or progressive MS to IV autologous bone-marrow MSCs or placebo, then switched groups. The infusions were safe and well tolerated.
Umbilical cord MSCs across conditions
A 2026 systematic review in Stem Cells Translational Medicine (Hum and colleagues) analyzed 42 randomized trials with 2,280 patients receiving intravascular umbilical cord MSCs and found more temporary fever, with no signals of harm for infection, thrombosis, malignancy, abnormal tissue formation or death, and recommended continued long-term monitoring.
What this means
MSC therapy appears safe in MS in controlled studies. It is a supportive option that complements, rather than replaces, proven MS treatments.
Why immune balance matters in MS safety
MS is driven by immune cells that mistakenly attack myelin in the brain and spinal cord. Treatments that act on the immune system, whether medications or cells, have to balance two goals: reducing harmful immune activity while preserving the ability to fight infections. MSCs are thought to nudge the immune system toward regulation rather than suppressing it broadly, which is one reason they have not been associated with increased infections in controlled trials. However, when MSCs are given to someone who is already taking strong immune-suppressing medication, the overall picture becomes more complex. That is why the timing of your last DMT dose, recent blood counts and any history of serious infections are reviewed carefully, and why treatment decisions are made together with your neurologist.
MS-specific safety considerations
Fever and heat sensitivity (Uhthoff's phenomenon)
Many people with MS notice that heat or fever temporarily worsens symptoms such as fatigue, weakness, blurred vision or numbness. Because fever is the most common side effect of IV MSCs, some patients may experience a short-lived worsening of existing symptoms during the first day or two. This is called a pseudo-relapse; it is not new nerve damage and usually resolves as temperature returns to normal. Fever is monitored and treated promptly, typically with paracetamol and cooling measures.
Recent relapses
Treatment is usually postponed if you have had a relapse or a course of high-dose steroids recently, so the team can evaluate a stable baseline and avoid confusing effects.
Disease-modifying therapies (DMTs)
Many DMTs affect the immune system, some for months after a dose. Examples include anti-CD20 antibodies, natalizumab, fingolimod and similar drugs, cladribine and alemtuzumab. These influence infection risk and timing. DMTs should not be stopped without your neurologist's guidance; the medical team will review timing and coordinate with them.
Infections
People on immune-suppressing DMTs may be more vulnerable to infections. Treatment is postponed if there is an active infection, including urinary infections, which are common in MS.
Bladder, mobility and fatigue
Bladder urgency, mobility aids and fatigue are planned for during travel and the stay.
Intrathecal procedures
If a protocol involving delivery into the spinal fluid is discussed, it carries additional risks such as headache, back pain and, rarely, infection.
How we reduce risk
- Neurology record review: MS type, recent MRI, relapse history, EDSS, current DMT and dose timing.
- Stability requirement: no recent relapse or high-dose steroid course, and no active infection.
- Pre-treatment testing: complete blood count, metabolic panel, urinalysis and tumor markers.
- Quality-controlled cells: donor screening, infectious disease testing, and laboratory quality testing before release.
- Slow infusion with monitoring, including temperature; cooling measures available.
- Observation with nursing supervision.
- Coordination with your neurologist and clear instructions to distinguish pseudo-relapse from true relapse.
Long-term safety and monitoring
Clinical trials of MSCs in MS and other conditions have followed patients for months to a few years without showing increased rates of cancer, abnormal tissue growth or serious infections. Rare long-term effects can only be excluded with larger numbers of patients and longer follow-up, so continued monitoring is recommended. In MS, regular MRI scans and neurological assessments are already part of standard care, which makes it easier to track both safety and any changes after treatment. Keep these appointments, share your treatment records and report any unusual symptoms promptly.
Safety and benefit are separate questions
A treatment can be safe without changing the course of MS. High-efficacy DMTs and, for selected patients, aHSCT have the strongest evidence for controlling inflammatory activity. MSC therapy may be considered by people seeking a supportive approach, particularly with progressive symptoms, with realistic goals such as fatigue, mobility or quality of life, measured over time.
Regulatory context
No MSC product is approved by the FDA or the European Medicines Agency for MS. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS. Ask for documentation of the cell product and facility.
Who may be a safe candidate
- Confirmed MS diagnosis with stable disease, without a relapse or high-dose steroid course in recent weeks.
- DMT timing reviewed with the neurologist.
- No active infection, including urinary tract infection.
- No cancer within the past five years.
- Ability to travel safely, with support if mobility or fatigue are limiting.
- Realistic goals and willingness to continue standard MS care.
Preparing for treatment
Share recent MRI reports, neurology notes and your complete medication list, including your DMT and the date of your last dose. Plan travel with rest, temperature control and accessible accommodations. Bring cooling items if heat affects you. Keep a short baseline of your symptoms, such as walking time or fatigue scores, to help evaluate changes later. If you use a catheter or have a bladder management routine, share it with the nursing team so it can be continued during your stay, and ask about rest areas and accessible bathrooms along the travel route.
Signs to report after treatment
Contact the team or your neurologist for new neurological symptoms lasting more than 24 hours without fever (possible relapse), high or persistent fever, signs of infection, severe headache, shortness of breath or chest pain.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
- An additional intrathecal application (similar to an epidural, usually about 60 million cells) for some neurological conditions, only after the doctor reviews your medical reports and confirms you are a candidate.
- One night at our facilities, sometimes two, with nursing and medical monitoring.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.
Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.
Questions to ask during your evaluation
- Is this MSC therapy or HSCT, and what are the specific risks?
- How does my DMT affect timing and safety?
- How will fever be managed given my heat sensitivity?
- How will we distinguish a pseudo-relapse from a true relapse?
- How will you coordinate with my neurologist?
Bottom line
MSC therapy for multiple sclerosis has a favorable safety record in randomized trials, with temporary fever as the most common side effect; in MS, fever can briefly worsen existing symptoms, so monitoring and planning matter. MSC therapy is distinct from aHSCT, which is more intensive and carries greater risks. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your type of MS, current treatments and medical history.
References
- MS International Federation (MSIF): Stem cell therapy for MS (opens in a new tab)
- Uccelli A et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet Neurology, 2021 (opens in a new tab)
- Burt RK et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA, 2019 (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
